Cargando…
Predicting PD-L1 expression status in patients with non-small cell lung cancer using [(18)F]FDG PET/CT radiomics
BACKGROUND: In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the available ICI therapy strategies, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors are the most wide...
Autores principales: | Zhao, Xiaoqian, Zhao, Yan, Zhang, Jingmian, Zhang, Zhaoqi, Liu, Lihua, Zhao, Xinming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868196/ https://www.ncbi.nlm.nih.gov/pubmed/36682020 http://dx.doi.org/10.1186/s13550-023-00956-9 |
Ejemplares similares
-
Baseline (18)F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma
por: Jing, Fenglian, et al.
Publicado: (2023) -
Value of pre-treatment (18)F-FDG PET/CT radiomics in predicting the prognosis of stage III-IV colorectal cancer
por: Wang, Na, et al.
Publicado: (2023) -
Pre-Clinical Study of the [(18)F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer
por: Han, Jingya, et al.
Publicado: (2022) -
Performance of (18)F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer
por: Zhang, Min, et al.
Publicado: (2020) -
Quantitative classification and radiomics of [(18)F]FDG-PET/CT in indeterminate thyroid nodules
por: de Koster, Elizabeth J., et al.
Publicado: (2022)